Methylphenylsulfone

Methylphenylsulfone

SCHEMBL28291817

CS(=O)(=O)c1ccccc1.Oc1ccccc1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.70
PTGS2 P35354 9/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
GLA P06280 1/20 0.52
CA3 P07451 1/20 0.52
CA4 P22748 1/20 0.52
CA9 Q16790 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
CA14 Q9ULX7 1/20 0.52
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HTR6 P50406 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylphenylsulfone SCHEMBL78253 0.87 PTGS2 (0.62) ENPP2PTGS2CA12CA1CA2
Methylphenylsulfone SCHEMBL1332357 0.87 PTGS2 (0.62) ENPP2PTGS2CA12CA1CA2
Methylphenylsulfone SCHEMBL5499087 0.85 PTGS2 (0.60) ENPP2PTGS2CA12CA1CA2
Methylphenylsulfone SCHEMBL561404 0.83 PTGS2 (0.54) ENPP2PTGS2TSHRSMN1; SMN2HTR6
Methylphenylsulfone SCHEMBL28288198 0.82 PTGS2 (0.58) ENPP2PTGS2CA12CA1CA2
Methylphenylsulfone SCHEMBL28158010 0.82 PTGS2 (0.58) ENPP2PTGS2CA12CA1CA2
Methylphenylsulfone SCHEMBL28046614 0.82 PTGS2 (0.58) ENPP2PTGS2CA12CA1CA2
SCHEMBL1535 0.82 ENPP2 (1.00) ENPP2PTGS2CA12CA1CA2
Methylphenylsulfone SCHEMBL28097901 0.82 PTGS2 (0.58) ENPP2PTGS2CA12CA1CA2
Phenol SCHEMBL94009 0.82 CA1 (0.61) ENPP2CA12CA1CA2GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563103-A modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto 艾尼纳制药公司 2019-04-02 CN disclosed